natgillin/translations-raw huggingface dataset:
In some implementations, prior to (c), the methods include an operation of computationally removing allele frequencies for polymorphisms identified has being heterozygous in the pregnant individual. 
Postupak prema patentnim zahtjevima 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao heterozigotni kod trudne osobe.
A method of treating Alzheimer's disease, mild cognitive impairment, or abnormal accumulation or deposition of beta-amyloid in the central nervous system in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an antibody that specifically binds to beta-amyloid, wherein the antibody comprises: 
Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 ili 10 naznačeno time da je za uporabu za liječenje Alzheimerove bolesti, blagog kognitivnog poremećaja, ili abnormalnog nakupljanja ili taloženja beta-amiloida u središnjem živčanom sustavu kod čovjeka.
A-compound having a formula selected from the group consisting of: and 
Spoj naznačen time da ima formulu odabranu iz skupine koju čine:
or a pharmaceutically acceptable acid addition salt thereof, or a solvate thereof. 
ili njegova farmaceutski prihvatljiva adicijska sol s kiselinom, ili njegov solvat.
Obviously, the particular knitting of the therapeutic hosiery item according to the invention may also be obtained by using the first drop and the third drop to form the first rows of knitting and the second and fourth drops to form the second rows of knitting. 
Očigledno, posebno pletivo terapeutske čarape prema izumu može se također dobiti i upotrebom prvog transportera i trećeg transportera za oblikovanje neparnih redova pletiva, te drugog i četvrtog transportera za oblikovanje parnih redova pletiva.
Aflibercept for use in treating a patient according to any one of claims 1 to 7 and 9 to 14, wherein the folinic acid, 5- fluorouracil (5-FU), irinotecan and aflibercept are administered intravenously every two weeks for a period comprised between 9 and 18 weeks. 
Aflibercept za uporabu u liječenju pacijenta prema bilo kojem od patentnih zahtjeva 1 do 7 1 9 do 14, naznačen time što se folinska kiselina, 5- fluorouracil (5-FU), irinotekan i aflibercept daju intravenozno svaka dva tjedna tijekom perioda koji se sastoji od između 9 i 18 tjedana.
In Experiment No. 2-1, there was no cement admixture used. 
Denka Company Limited, 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku,
R2a is selected from the group consisting of hydrogen and alkyl; or 
R* je odabran iz grupe koja se sastoji od vodika ili alkila; ili
A pharmaceutical combination of Claim 25 wherein the other therapeutic agent is selected from cyclosporins; cyclosporin A; anti-IL-2 receptor; anti-CD45RB; anti-CD2; anti-CD3 (OKT-3); anti-CD4; anti-CD80; anti-CD86; monoclonal antibody OKT3; agents blocking the interaction between CD40 and gp3 9; antibodies specific for CD40 and/or gp39; CD154; fusion proteins constructed from CD40 and gp39; CD40Ig; CD8gp39; nuclear translocation inhibitors of NF-kappa B function; deoxyspergualin; gold compounds; antiproliferative agents selected from methotrexate, FK506, tacrolimus, Prograf and mycophenolate mofetil; cytotoxic drugs selected from azathiprine and cyclophosphamide; anticytokines selected from antiIL-4 or IL-4 receptor fusion proteins; PDE 4 inhibitors including Ariflo and PTK inhibitors. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je drugo terapijsko sredstvo odabrano od ciklosporina, ciklosporin A, anti-IL-2 receptora, anti-CD45RB, anti-CD2, anti-CD3 (OKT-3), anti-CD4, anti-CD80, anti-CD86, monoklonalnog protutijela OKT3, sredstava za blokiranje interakcije između CD40 i gp39, protutijela specifičnih za CD40 i/ili gp39, CD 154, fuzijskih proteina konstruiranih od CD40 i gp39, CD40Ig, CD8gp39, inhibitora translokacije jezgre od NF-kapa B funkcije, deoksispergualina, spojeva sa zlatom, antiproliferacijskih sredstava koji su izabrani od metotreksat, FK506, takrolimus, Prografimikofenolat mofetila, citotoksični lijekovi koji su odabrani od azatiprina i ciklofosfamida, anticitokini koji su odabrani od antiIL-4 ili IL-4 receptora fuzijskih proteina, PDE 4 inhibitori, uključujući Ariflo i PTK inhibitore.
A preferred oral dose of netupitant ranges from about 50 to 500 mg, or from about 200 to about 400 mg, but is preferably about 300 mg. 
Farmaceutski pripravak prema patentnim zahtjevima 1-2, naznačen time što navedena terapeutski efikasna količina netupitanta sadrži od oko 200 do oko 400 mg netupitanta ili njegove farmaceutski prihvatljive soli.
<400> 12 A human anti-CD40 monoclonal antibody that is capable of specifically binding to a human CD40 antigen expressed on the surface of a human CD40-expressing cell, said monoclonal antibody being free of significant agonist activity when bound to the CD40 antigen expressed on the surface of said cell, for use in a method for treating a human subject for an inflammatory disease or autoimmune disease, the method comprising administering to said subject an effective amount of the human anti-CD40 monoclonal antibody, said human anti-CD40 monoclonal antibody being selected from the group consisting of: 
Humano monoklonalno antitijelo koje se može specifično vezati za humani CD40 antigen koji je eksprimirao na površini humane CD40-ekspresijske stanice, navedeno monoklonalno antitijelo je slobodno od značajnog agonističkog djelovanja, gdje, kada se navedeno monoklonalno antitijelo veže za CD40 antigen eksprimirani na površini navedene stanice, rast ili diferencijacija navedene stanice je inhibirana, gdje je navedeno antitijelo odabrano od skupine koja se sastoji od: a) monoklonalnog antitijela koje se veže za epitop koji može vezati monoklonalno antitijelo CHIR-5.9 koje se dobiva iz hibridomske stanične linije koja je pohranjena kod tvrtke American Type Culture Collection (dalje u tekstu ATCC) kao Patentna pohrana br.
The liquefied gas treatment system according to claim 2, wherein the BOG, which is liquefied by the heat exchanger and decompressed by the decompressing means, is returned to the cargo tank. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se treću struju, ukapljenu u izmjenjivaču topline (21), dekomprimira elementom za dekomprimiranje (22).
The dryer of claim 4 in wherein the apertured plates are constructed with baffles which incline downwardly over the apertures in the plates and into the vertical path when the plates are moving downwardly along the vertical path. 
Sušilica prema patentnom zahtjevu 4 kod koje su ploče (70, 80) sa otvorima konstruirane sa odbojnim pločama koje su nagnute prema dole preko otvora u pločama (70, 80) 1 u vertikalnoj putanji kada se ploče (70, 80) pomiču prema dole duž vertikalne putanje.
the sum total of the 5' and the 3' homology arms of the LTVEC is from about 16 kb to about 150 kb. 
(b) zbroj ukupnih 5' i 3' homolognih dijelova LTVEC-a je od oko 16 kb do oko 150 kb.
Wind system (1) according to claim 1, characterised in that said kites (2) are equipped with an actuating and stabilising system of a sideslip manoeuvre. 
Vjetreni sustav (1) prema zahtjevu 6, naznačen time da je spomenuta rastegnuta fleksibilna konstrukcija (12) opremljena jednom okomitom rešetkastom konstrukcijom (13).
The peptide of any one of aspects 1-8, wherein the peptide comprises two residues separated by three or six residues that are linked by a hydrocarbon linkage. The peptide of aspect 9, wherein the peptide comprises the amino acid sequence of: 
Peptid bilo kojeg patentnog zahtjeva od 1-3, pri čemu peptid sadrži odvojena po tri ili šest ostataka koji su vezani ugljikovodičnom vezom, pri čemu opcijski peptid sadrži aminokiselinski slijed: aa) KWRS.AGWR,WRLWRVRSWSR (ID BR.
The peptide for use according to Claim 1 or 2, wherein said peptide is part of a fusion protein. 
Peptid u skladu s patentnim zahtjevom 1 ili 3, pri čemu je navedeni peptid dio fuzijskog proteina.
Such inks are formulated on the basis of optically variable pigment (OVP), a preferred type of OVP being the flaky thin-film optical interference device described in U.S. Pat. No. 4,705,300; U.S. Pat. No. 4,705,356; U.S. Pat. 
Takve se tinte proizvode na temelju optički varijabilnog pigmenta (OVP), a poželjan oblik OVP-a čini pahuljasto tankoslojno sredstvo za optičku interferenciju opisano u US 4,705,300; US 4,705,356; US 4,721,217; US 4,779,898; US 4,930,866; US 5,084,351 i povezanim objavama.
The matches 9 are located either alongside or crosswise the box. 
Å ibice 9 su smještene bilo uzduž bilo poprijeko kutije.
The RNAi agent or pharmaceutical composition for use of claim 12, wherein one of the 3 nucleotide differences in the nucleotide sequence of the antisense strand is a nucleotide mismatch in the seed region of the antisense strand, wherein preferably the antisense strand comprises a universal base at the mismatched nucleotide; and/or 
RNAi sredstvo ili farmaceutski pripravak za uporabu prema zahtjevu 12, naznačeno time da (a) jedna od 3 nukleotidne razlike u nukleotidnoj sekvenci protusmjernog lanca je nukleotidna neusklađenost u sjemenskoj regiji protusmjernog lanca, pri čemu protusmjerni lanac poželjno sadrži univerzalnu bazu na neusklađenom nukleotidu; i/ili
Compound of Example 1 
Spoj iz Primjera 1
EP 744 746 and EP 874 768 discloses systems comprising metal. 
EP 744 746 i EP 874 768 otkrivaju sustav koji obuhvaća metal.
The method according to one of the preceding claims, wherein the step of measuring at least one further physical quantity comprises measuring a distance between the anchor and a fixed reference point, in particular measuring a distance between the anchor and a water vessel (2), and/or measuring an inclination or orientation of the anchor. 
5. Postupak prema jednom od prethodnih patentnih zahtjeva, pri čemu korak mjerenja najmanje jedne daljnje fizikalne veličine obuhvaća mjerenje udaljenosti između sidra 1 fiksne referentne točke, osobito mjerenje udaljenosti između sidra 1 plovila (2) 1ili mjerenje nagiba ili orijentacije sidra.
wherein Z is a peptide moiety having the formula (II): (II) 
-Z-R2 (I) naznačen time da Z je peptidni dio koji ima formulu (II) [image]
The invention further concerns a nucleic acid molecule that encodes a polypeptide chain of any of the above-described dual affinity retargeting reagents (DART™s). 
Molekula nukleinske kiseline, naznačena time što kodira polipeptid lanac molekule koja se veže na B7-H3 u skladu s bilo kojim od patentnih zahtjeva 1-10.
moving the container of dehydrated organic material through the equilibration chamber from the input end to a discharge end thereof, while allowing the dehydrated organic material to cool; and unloading the container of cooled, dehydrated organic material from the equilibration chamber at the discharge end thereof. 
pokretanja posude dehidriranog organskog materijala kroz ekvilibracijsku komoru od njenog ulaznog kraja (155) do kraja (158) za pražnjenje, dok se dozvoljava dehidriranom organskom materijalu da se ohladi; i istovar posude ohlađenog, dehidriranog organskog materijala iz ekvilibracijske komore (150) na kraju (158) za pražnjenje iste.
The membrane filters were incubated on petri-dishes comprising the following media: 
Membranski filtri su inkubirani u petrijevim zdjelicama koje su sadržavale slijedeće hranjive podloge:
placing a strip of a desiccant polymer or a desiccant film in each bottle containing the homogeneous suspension before sealing the bottle. 
C) = postavljanje trake polimera za sušenje ili filma za sušenje u izravni dodir s homogenom suspenzijom u navedenoj boci prije zatvaranja boce.
under a slight slack, the second cup-shaped body portion 140, which is attached to the upper portion of the upright member 11 . 
može ga se blago cimati, drugi trup u obliku šalice 140, pričvršćen na gornji dio uspravnog elementa 11.
Use of a compound according to any one of claims 1 to 3 for the treatment of conditions or disorders mediated by S1 P1 receptors. Use according to claim 4, wherein the condition or disorder is multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju stanja ili poremećaja povezanih s receptorima S1P1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori i tumorske metastaze, bolesti povezane s angiogenezom, vaskularne bolesti, bolna stanja, akutne virusne bolesti, upalna crijevna stanja, dijabetes ovisan o inzulinu i dijabetes neovisan o inzulinu.
wherein said neck (6) comprises a threaded portion distinct from said dome (41) and applied to said dome (41), said threaded portion being arranged for engaging a further threaded portion of said cap (7); 
Naznačeno time da se navedeno grlo (6) sastoji od dijela s navojem odvojenog od navedene kupole (41) i koji se nanosi na navedenu kupolu (41), s tim da je dio s navojem postavljen tako da se povezuje s daljnjim dijelom s navojem na navedenom poklopcu (7);
for use in the treatment or prevention of pneumonia; and/or for use in the treatment or prevention of H. influenzae infection or disease. The fusion protein, the immunogenic composition, or the vaccine of claims 1-19 for use in the treatment or prevention of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). 
– namijenjen upotrebi u liječenju ili sprječavanju akutnih pogoršanja kronične opstruktivne plućne bolesti (AECOPD); i/ili – namijenjen upotrebi u liječenju ili sprječavanju pneumonije; i/ili – namijenjen upotrebi u liječenju ili sprječavanju zaraze ili bolesti uzrokovane bakterijom H. influenzae.
8 shows the discharge device 1 in the first position. 
Slika & pokazuje napravu za pražnjenje 1 u prvom položaju.
The process of paragraph 46, wherein said first base is selected from the group consisting of triethylamine; 1,5-diazabicyclo[4,3,0]non-5-ene 1,4-diazabicyclo[2,2,2]octane; and 1,8-diazabicyclo[5,4,0]undec-7-ene; and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, wherein saidprvu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.O0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; i 1,8-diazabiciklo[5.4.O0]undec-7-en; te smjese 2 ili višo njih.
In an aspect, the present invention relates to a pharmaceutical formulation comprising an erosion matrix which comprises: % to 80 %, such as 20 % to 70 %, such as 20 % to 60 %, such as 30 % to 60 %, such as 35 % to 60 %, such as 35 % to 55 %, such as 40 % to 55 %, such as 40 % to 50 %, such as 44 % to 55 %, such as 42 % to 48 %, by weight of one or more fumaric acid esters selected from di-(C1-C5)alkylesters of fumaric acid and mono-(Ci-C5)alkylesters of fumaric acid, or a pharmaceutically acceptable salt thereof, as an active substance; 
HR P20130480 T1 PATENTNI ZAHTJEVI zoo n Farmaceutska formulacija u obliku tablete erozijskog matriksa, naznačena time, da obuhvaća: i) kao aktivnu tvar jedan ili više estera fumarne kiseline odabranih od di-(C,-Cs)alkilestera fumarne kiseline 1 mono-(C,-Cs)alkilestera fumarne kiseline od 10% do 80% po masi, ili farmaceutski prihvatljivu sol od istih; 1i) jedan ili više sredstava za kontrolu učestalosti od 1 do 50% po masi; i enteričku oblogu, pri čemu se ta enterička obloga nanosi na razini od 1,5 do 3,5% po masi jezgre, gdje erozija od spomenutog erozijskog matriksa dopušta kontrolirano ili potpomognuto oslobađanje spomenute aktivne tvari.
The drying time in the fluid-bed dryer was 19 minutes. 
Vrijeme sušenja u sušilu fluidnog ležišta bilo je 19 minuta.
The crystal of the orthorhombic form of the present invention can also be characterized, and thus distinguished from the monoclinic form, by their Raman spectra. 
Kristal ortorombskog oblika u ovom izumu također se može karakterizirati, te stoga razlučiti od monoklinskog oblika, putem njihovog Ramanovog spektra.
Package according to anyone of claims 1 to 14, characterised by a reinforcement insert inserted into the inner shell (6; 96; 106, 107). 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što je umetak za pojačanje umetnut u unutarnju ljusku (6; 96; 106, 107; 116).
A human or animal cytomegalovirus (CMV) vector comprising: 
PATENTNI ZAHTJEVI Humani ili životinjski citomegalovirusni vektor, naznačen time, da sadržava:
As is known, the gasifier is useful for synthesizing a hydrogen lean or deficient synthesis gas (syngas) stream in a non-catalytic partial oxidation reaction. 
(a) formuliranja struje sinteznog plina siromašne vodikom reakcijom nekatalitičke djelomične oksidacije;
Starting material of formula VI may be prepared from compounds of formula VII. EXAMPLES 
Polazna supstanca formule VI može se pripraviti iz spojeve formule VII. PRIMJERI
In this device, oil-well tubing (OWT) fitted with metal rings with slits, is a casing and at the same time a magnetic core. 
U ovom je uređaju cjevovod naftnog izvora (CNI), postavljen s metalnim obručima koji imaju otvore, istovremeno zaštita (omot) i magnetska jezgra.
A composition for use according to Claim 1 or a composition as claimed in Claim 8, wherein the cyclodextrin is present in said aqueous solution at a concentration of 25% or 40% (w/v) of the composition. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je ciklodekstrin prisutan u navedenoj vodenoj otopini u koncentraciji od 25% ili 40% (tež./vol.) pripravka.
Aaa is an amino acid residue selected from Ser, Asn or Thr, optionally substituted by alkyl; wherein the C-terminus thereof is a free terminus, is amidated, or is esterified; and 
je vodik ili -CO-Aaa; Aaa je aminokiselinski ostatak, kojeg se bira između Ser, Asn i Thr; gdje je njegov C-kraj slobodni kraj, amidiran ili esterificiran;
The compound of claim 1 or claim 10, wherein G is phenyl, pyridyl, cyclohexyl, cyclopentyl or benzyl, and is substituted with R3 and R4. 
Spoj prema zahtjevu 1 ili zahtjevu 10, naznačen time, da G je fenil, piridil, cikloheksil, ciklopentil ili benzil, i supstituiran je s R3 i R4.
The method is characterized in that the administration takes place by nasal administration. 
Postupak je karakteriziran time da je primjena nazalna primjena.
a light chain CDR1 having the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 19, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 20, a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 22, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 23, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 24; or 
izoliranom protutijelu, ili njegovom antigenski vežućem fragmentu, specifičnom za folatni receptor a (FRa), koje ima CDR1 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 18, CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 19, CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 20, CDR1 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 22, CDR2 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 23, te CDR3 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 24;
The overall conclusion of the statistical evaluation was that "there is a tendency to significance: sugar-free cookies are preferred over sugar-containing cookies". 
Ukupni je zaključak, utemeljen na statističkoj analizi bio da Â«postoji tendencija k značajnosti: kolačima bez šećera daje se prednost pred kolačima pripravljenima sa šećerom».
The apparatus 1 according to the present invention can carry out its principal activity on its own, but it is to be noted that it can connect to other apparatuses 1 by means of, for example, a computer network 14 and/or a telephone network 13, in order to let it exchange data to and from the said other apparatuses (see FIG. 4). 
Uređaj 1 koji je u skladu s predmetnim izumom može obavljati svoju osnovnu djelatnost sa za scbe, ali treba napomenuti da on može biti spojen na druge uređaje 1 pomoću, na primjer, kompjutorske mreže 14 i/ili telefonske mreže 13, da bi se omogućila izmjena podataka prema ovim drugim navedenim uređajima ili od ovih drugih navedenih uređaja (vidi sliku 4).
The solid form of claim 31, further comprises peaks at approximately 17.65, 22.47, and 26.77 degrees 2θ. 
Čvrsti oblik prema zahtjevu 1, naznačen time što XRPD uzorak nadalje sadrži vrhove na približno 17.65, 22.47 i 26.77 stupnjeva 20.
In a specific embodiment of the present invention the method is characterized in that said method results in increased specific cellular productivity of said protein of interest in said cell in comparison to a control cell previously transfected with a polynucleotide encoding for the protein of interest, but whereby said control cell does not have increased expression of a protein having an amino acid sequence comprising a steroidogenic acute regulatory related lipid transfer (START) domain or a derivative or mutant thereof. 
Postupak prema zahtjevima od 1 do 5, naznačen time, da, spomenuti postupak rezultira s povećanjem specifične stanične produktivnosti spomenutog korisnog proteina u spomenutoj stanici, u usporedbi sa kontrolnom stanicom za ekspresiju spomenutog korisnog proteina, ali pri čemu spomenuta kontrolna stanica nema povećanje ekspresije niti djelovanja proteina s amino-kiselinskom sekvencom, koja sadrži ceramidni prijenosni protein CERT ili njegov derivat ili njegov mutant.
Method according to claim 1, characterized in that the part flows are created by means of part channels, the lengths of which diminish from the edges towards the emission flow. 
Postupak sukladno zahtjevu 1 ili 2, naznačen time, da se djelomični tokovi kreiraju pomoćnim parcijalnih kanala, čija se duljina proteže od krajeva u smjeru protoka emisije.
The monoclonal antibody of any one of claims 1 to 7, which increases at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal, or which blocks the inhibitory effect of sclerostin in a cell-based mineralization assay. 
Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 10 do 16, naznačen time, da povećava najmanje jednu koštanu formaciju, mineralnu koštanu gustoću, sadržaj minerala u kosti, koštanu masu, kvalitetu kosti i čvrstinu kosti u sisavca ili koja blokira inhibitorni učinak sklerostina u testu mineralizacije koji se temelji na stanici.
The method according to claim 9, wherein the flowable polymer material is applied with a nozzle onto the inner side of the vessel closure. 
Zatvarač prema zahtjevu 9, naznačen time da se tekući polimerni materijal nanosi iz mlaznice u unutrašnjost zatvarača posude.
The pressureless accumulator (1) according to claim 7, characterized in that the float supported tube (28) is connected to the at least one heat emitting system and to the at least one heat absorbing system via a first inlet/outlet channel (30). 
Akumulacijski spremnik bez pritiska (1) prema zahtjevu 6, naznačen time da je cijev poduprta s plovkom (28) spojena na barem jedan sustav za emitiranje topline i na barem jedan sustav za apsorbiranje topline putem prvog kanala za ulaz/izlaz (30).
The compound for use according to claim 1, wherein the hyperproliferative disorder is breast cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da je hiper-proliferativni poremećaj rak dojke.
A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable auxiliary. 
Farmaceutska kompozicija koja sadrži spoj koji je spoj koji ima strukturu: